Cerus Corporation ( (CERS) ) has released its Q1 earnings. Here is a breakdown of the information Cerus Corporation presented to its investors.
Cerus Corporation is a Concord, California-based company focused on enhancing the safety and availability of blood components through its INTERCEPT Blood System, which is globally recognized for pathogen reduction in blood products.
In its first quarter of 2025, Cerus Corporation reported a 13% increase in product revenue, reaching $43.2 million, and maintained its full-year revenue guidance between $194 million and $200 million. The company also highlighted significant progress with its next-generation LED-based illumination device, INT200, and an updated CE Mark application for its INTERCEPT red blood cell system.
Key financial metrics for the quarter included a total revenue of $48.9 million, with government contract revenue contributing $5.6 million. The company’s product gross profit rose by 20% to $25.4 million, and its product gross margin improved to 58.8%. Despite a net loss of $7.7 million, Cerus achieved a positive non-GAAP adjusted EBITDA of $0.2 million, marking a significant improvement from the previous year’s negative $2.7 million.
Looking ahead, Cerus Corporation remains optimistic about its growth prospects, driven by expected revenue increases and improved gross margins. The company is committed to achieving positive full-year non-GAAP adjusted EBITDA and aims to establish its INTERCEPT Blood System as the global standard for blood safety.